Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.77 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.70 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.70 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.70 |
| ▸ | PLD1 | Q13393 | 3/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | PLD2 | O14939 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7961184 | 0.87 | OPRM1 (1.00) | OPRM1OPRD1OPRK1OPRL1PLD1 | |
| SCHEMBL4918579 | 0.85 | OPRM1 (0.67) | OPRM1OPRD1OPRK1OPRL1PLD1 | |
| SCHEMBL25160058 | 0.84 | OPRM1 (0.60) | OPRM1OPRD1OPRK1OPRL1PLD1 | |
| SCHEMBL4152396 | 0.84 | CYP2D6 (0.70) | OPRM1OPRD1OPRK1OPRL1PLD1 | |
| SCHEMBL14410199 | 0.84 | OPRM1 (0.56) | OPRM1OPRD1OPRK1OPRL1PLD1 | |
| SCHEMBL319049 | 0.83 | CHRM1 (0.70) | OPRM1OPRK1OPRL1PLD1CHRM2 | |
| SCHEMBL9057334 | 0.83 | OPRM1 (0.91) | OPRM1OPRD1OPRK1OPRL1CHRM2 | |
| SCHEMBL31422682 | 0.83 | OPRM1 (0.75) | OPRM1OPRD1OPRK1OPRL1PLD1 | |
| SCHEMBL31422674 | 0.83 | OPRM1 (0.71) | OPRM1OPRD1OPRK1OPRL1PLD1 | |
| SCHEMBL9057503 | 0.83 | OPRM1 (0.91) | OPRM1OPRD1OPRK1OPRL1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210113534-A1 | COMPOUNDS | THE UNIVERSITY OF SHEFFIELD (GB) | 2021-04-22 | — | — | US | disclosed |
| US-10172821-B2 | Histone deacetylase inhibitors | President & Fellows of Harvard College Dana-Farber Cancer Institute, Inc. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9199923-B2 | Histone deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150038581-A1 | HISTONE DEACETYLASE INHIBITORS | Harvard University & Medical School | 2015-02-05 | — | — | US | disclosed |
| US-8334290-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8304451-B2 | Histone deacetylase and tubulin deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-11-06 | — | — | US | disclosed |
| US-8202861-B2 | Drugs for various disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-19 | — | — | US | disclosed |
| US-8178579-B2 | Histone deacetylase inhibitors; anticancer agents; antiprotozoa agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-15 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080070916-A1 | Dihydropyrancarboxamides and uses thereof | SCHREIBER STUART L | 2008-03-20 | — | — | US | disclosed |
| US-7244853-B2 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-17 | — | — | US | disclosed |
| WO-2007070173-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-7186709-B2 | Subjecting a vinyl ethers and an unsaturated ketoester to suitable conditions to generate a scaffold having the core dihydropyrancarboxamide or dihydropyrancarboxylic ester or acid; anticarcinogenic agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-03-06 | — | — | US | disclosed |
| US-7166600-B2 | Thiocarbamate inhibitors of alpha-4 integrins | GENENTECH, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| US-20040072849-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070916-A1 | Dihydropyrancarboxamides and uses thereof | CCNA1, DPYD, DHFR | OPRM1 3615/4885OPRD1 3017/4885OPRK1 2560/4885 |
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | OPRM1 4883/4885OPRD1 4699/4885OPRK1 4828/4885 |
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | DRD4, DRD2, SLC6A3 | OPRM1 87/4885OPRD1 18/4885OPRK1 45/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | OPRM1 1290/4885OPRD1 916/4885OPRK1 651/4885 |
| US-20040072849-A1 | Dioxanes and uses thereof | UTS2R, HDAC5, AMDHD2 | OPRM1 4575/4885OPRD1 4216/4885OPRK1 4629/4885 |
| US-20150038581-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | OPRM1 4883/4885OPRD1 4699/4885OPRK1 4828/4885 |
| US-20210113534-A1 | COMPOUNDS | MRGPRX2, MC2R, ADM2 | OPRM1 124/4885OPRD1 264/4885OPRK1 257/4885 |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | CD22, ITGAM, FCGR3B | OPRM1 2091/4885OPRD1 1182/4885OPRK1 2059/4885 |
| US-10172821-B2 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC7 | OPRM1 4883/4885OPRD1 4699/4885OPRK1 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.